[Postoperative therapy using human atrial natriuretic peptide in cases of valve replacement]

What Was Tested

This controlled clinical trial paper looks at ANP (Atrial Natriuretic Peptide).

First, to examine the relationship between preoperative level of hANP and cardiac function, the relationship between preoperative level of hANP and history of cardiac failure and pulmonary artery wedge pressure (PAWP) were evaluated.

Why It Was Studied

The effect of hANP (atrial natriuretic peptide) was investigated clinically in 40 patients who underwent isolated valve replacement.

Patients were divided into four groups: aortic regurgitation (AR), aortic stenosis (AS), mitral regurgitation (MR) and mitral stenosis (MS).

Who Took Part

The study group was 40 patients.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

What Was Measured

The researchers measured the levels of hANP and c-GMP and blood pressure, pulmonary artery pressure, central venous pressure and levels of Na, K of urine and blood prcoperatively, immediately postoperatively and 1, 2, 4, 6 hours after operation.

Also, the researchers evaluated the relationship between preoperative level of hANP and each dimension on echocardiography.

The subject headings attached to it are Aortic Valve Insufficiency, Aortic Valve Stenosis, Atrial Natriuretic Factor, Heart Valve Diseases, Heart Valve Prosthesis Implantation, Mitral Valve Insufficiency and Mitral Valve Stenosis.

What This Means in Plain Language

This is a controlled clinical trial of ANP (Atrial Natriuretic Peptide) in 40 patients.

The publication is from 1998 (The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi), a journal based in Japan.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.